Despite the similarities in gene expression between these models, there are clear differences in the oncogenic potential of IGFIR and EGFR in the mouse lung as tumor onset occurs much more rapidly in the mutant EGFR models (4–8 weeks versus 8–9 months in SPC-IGFIR mice). This evidence concerns the gene SFTPC and neoplasm.